% alzhub.org library filter
% Source: https://alzhub.org/research?author=van+Dyck+CH&atag=randomized
% 20 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{turner2015-26362286,
  author  = {Turner, R. S. and Thomas, R. G. and Craft, S. and van Dyck, C. H. and Mintzer, J. and Reynolds, B. A. and Brewer, J. B. and Rissman, R. A. and others},
  title   = {{A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease}},
  journal = {Neurology},
  year    = {2015},
  doi     = {10.1212/wnl.0000000000002035},
  pmid    = {26362286},
  url     = {https://doi.org/10.1212/wnl.0000000000002035}
}

@article{vandyck2023-36449413,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and others},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2212948},
  pmid    = {36449413},
  url     = {https://doi.org/10.1056/nejmoa2212948}
}

@article{honig2024-38730496,
  author  = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others},
  title   = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01441-8},
  pmid    = {38730496},
  url     = {https://doi.org/10.1186/s13195-024-01441-8}
}

@article{aisen2008-18854539,
  author  = {Aisen, P. S. and Schneider, L. S. and Sano, M. and Diaz-Arrastia, R. and van Dyck, C. H. and Weiner, M. F. and Bottiglieri, T. and Jin, S. and others},
  title   = {{High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial}},
  journal = {JAMA},
  year    = {2008},
  doi     = {10.1001/jama.300.15.1774},
  pmid    = {18854539},
  url     = {https://doi.org/10.1001/jama.300.15.1774}
}

@article{sano2011-21795660,
  author  = {Sano, M. and Bell, K. L. and Galasko, D. and Galvin, J. E. and Thomas, R. G. and van Dyck, C. H. and Aisen, P. S.},
  title   = {{A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e318228bf11},
  pmid    = {21795660},
  url     = {https://doi.org/10.1212/wnl.0b013e318228bf11}
}

@article{vandyck2023-22dd8fce,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and Reyderman, L. and Cohen, S. and Froelich, L. and Katayama, S. and Sabbagh, M. and Vellas, B. and Watson, D. and Dhadda, S. and Irizarry, M. and Kramer, L. D. and Iwatsubo, T.},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {New England Journal of Medicine},
  year    = {2023},
  pmid    = {36449413}
}

@article{coric2012-22892585,
  author  = {Coric, V. and van Dyck, C. H. and Salloway, S. and Andreasen, N. and Brody, M. and Richter, R. W. and Soininen, H. and Thein, S. and others},
  title   = {{Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease}},
  journal = {Archives of neurology},
  year    = {2012},
  doi     = {10.1001/archneurol.2012.2194},
  pmid    = {22892585},
  url     = {https://doi.org/10.1001/archneurol.2012.2194}
}

@article{cummings2018-29695589,
  author  = {Cummings, J. L. and Cohen, S. and van Dyck, C. H. and Brody, M. and Curtis, C. and Cho, W. and Ward, M. and Friesenhahn, M. and others},
  title   = {{ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005550},
  pmid    = {29695589},
  url     = {https://doi.org/10.1212/wnl.0000000000005550}
}

@article{coric2015-26414022,
  author  = {Coric, V. and Salloway, S. and van Dyck, C. H. and Dubois, B. and Andreasen, N. and Brody, M. and Curtis, C. and Soininen, H. and others},
  title   = {{Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2015},
  doi     = {10.1001/jamaneurol.2015.0607},
  pmid    = {26414022},
  url     = {https://doi.org/10.1001/jamaneurol.2015.0607}
}

@article{mintzer2021-34570180,
  author  = {Mintzer, J. and Lanctôt, K. L. and Scherer, R. W. and Rosenberg, P. B. and Herrmann, N. and van Dyck, C. H. and Padala, P. R. and Brawman-Mintzer, O. and others},
  title   = {{Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2021.3356},
  pmid    = {34570180},
  url     = {https://doi.org/10.1001/jamaneurol.2021.3356}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{sevigny2008-19015485,
  author  = {Sevigny, J. J. and Ryan, J. M. and van Dyck, C. H. and Peng, Y. and Lines, C. R. and Nessly, M. L. and {MK-677 Protocol 30 Study Group}},
  title   = {{Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial}},
  journal = {Neurology},
  year    = {2008},
  doi     = {10.1212/01.wnl.0000335163.88054.e7},
  pmid    = {19015485},
  url     = {https://doi.org/10.1212/01.wnl.0000335163.88054.e7}
}

@article{mulnard2000-10697060,
  author  = {Mulnard, R. A. and Cotman, C. W. and Kawas, C. and van Dyck, C. H. and Sano, M. and Doody, R. and Koss, E. and Pfeiffer, E. and others},
  title   = {{Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study}},
  journal = {JAMA},
  year    = {2000},
  doi     = {10.1001/jama.283.8.1007},
  pmid    = {10697060},
  url     = {https://doi.org/10.1001/jama.283.8.1007}
}

@article{vandyck2007-17545739,
  author  = {van Dyck, C. H. and Tariot, P. N. and Meyers, B. and Malca Resnick, E. and {Memantine MEM-MD-01 Study Group}},
  title   = {{A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2007},
  doi     = {10.1097/wad.0b013e318065c495},
  pmid    = {17545739},
  url     = {https://doi.org/10.1097/wad.0b013e318065c495}
}

@article{vandyck2019-31329216,
  author  = {van Dyck, C. H. and Nygaard, H. B. and Chen, K. and Donohue, M. C. and Raman, R. and Rissman, R. A. and Brewer, J. B. and Koeppe, R. A. and others},
  title   = {{Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2019},
  doi     = {10.1001/jamaneurol.2019.2050},
  pmid    = {31329216},
  url     = {https://doi.org/10.1001/jamaneurol.2019.2050}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{karlawish2008-18310554,
  author  = {Karlawish, J. and Kim, S. Y. and Knopman, D. and van Dyck, C. H. and James, B. D. and Marson, D.},
  title   = {{The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment}},
  journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
  year    = {2008},
  doi     = {10.1097/jgp.0b013e318162992d},
  pmid    = {18310554},
  url     = {https://doi.org/10.1097/jgp.0b013e318162992d}
}

@article{vandyck2006-16670247,
  author  = {van Dyck, C. H. and Schmitt, F. A. and Olin, J. T. and {Memantine MEM-MD-02 Study Group}},
  title   = {{A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil}},
  journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
  year    = {2006},
  doi     = {10.1097/01.jgp.0000203151.17311.38},
  pmid    = {16670247},
  url     = {https://doi.org/10.1097/01.jgp.0000203151.17311.38}
}

@article{schmitt2006-17132970,
  author  = {Schmitt, F. A. and van Dyck, C. H. and Wichems, C. H. and Olin, J. T. and {Memantine MEM-MD-02 Study Group}},
  title   = {{Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2006},
  doi     = {10.1097/01.wad.0000213860.35355.d4},
  pmid    = {17132970},
  url     = {https://doi.org/10.1097/01.wad.0000213860.35355.d4}
}

@article{vandyck2000-10665618,
  author  = {van Dyck, C. H. and Newhouse, P. and Falk, W. E. and Mattes, J. A.},
  title   = {{Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group}},
  journal = {Archives of general psychiatry},
  year    = {2000},
  doi     = {10.1001/archpsyc.57.2.157},
  pmid    = {10665618},
  url     = {https://doi.org/10.1001/archpsyc.57.2.157}
}